"

From 2012.igem.org

Revision as of 09:22, 3 October 2012 (view source) Fan12p (Talk | contribs) ← Older edit		Revision as of 18:57, 3 October 2012 (view source) Morgan.Howell (Talk | contribs) Newer edit →
Line 120:		Line 120:
	<li>		<li>
	<h2>Duke iGEM 2012</h2>		<h2>Duke iGEM 2012</h2>
-	<p>Our team is fully aware of it's disadvantages, being smaller than the rest, and holding less funding than the competition. However, these notions motivate each individual on the team rather than discourage us. We know that we will get out of this project, exactly what we put into it. Understanding this notion is why it is not unusual to find our team working 12 hour shifts daily. We are inspired and determined to contribute to the scientific community in a substantial way, utilizing our resources, and setting new standards.</p>	+	<p></p>
	</li>		</li>

---

Revision as of 18:57, 3 October 2012

Abstract

Medical genetic therapy has shown promise for improved accuracy in personalized genetic therapy of conditions such as Alzheimer’s disease and cancer. However, the speed of current medical genetic screening methods is limited by time-consuming rates of cell growth and gene expression. The goal of this work, therefore, was to develop a comprehensive platform for other researchers to use in further medical genetic studies. In yeast, an orthologous model of human gene function, we developed a system of two dimerizing fusion proteins to control two-hybrid mediated transcriptional activation in response to a 450 nm blue light (optogenetic) stimulus. After extensive characterization and optimization of our system, we compiled our methodologies into a physical toolkit, which contains custom yeast strains frozen in glycerol stocks, standardized plasmids, a stochastic network model, the design of a light pulse generator to induce gene expression, and a custom software package for rapid analysis of data. In the coming weeks, we will begin testing an application of our system by screening for orthologous suppressors of beta-amyloid that may be used in genetic therapy of Alzheimer’s disease. Our comprehensive toolkit streamlines identification of genetic therapeutic targets, and will speed progress toward personalized therapy of a variety of diseases.